Bio-Techne initiated with an Outperform at William Blair

William Blair analyst Matt Larew initiated coverage of Bio-Techne with an Outperform rating. The company is positioned to accelerate its above-market growth in cell and gene therapy through eventual ownership of Wilson Wolf, whose cell culture devices are used in more than 45% of all clinical C&GT trials, the analyst tells investors in a research note. The firm says Bio-Techne will provide both the “printer” and “ink” of C&GT trials.